Literature DB >> 8604228

Specificities and genetic characteristics of nucleosome-reactive antibodies from autoimmune mice.

M Monestier1, K E Novick.   

Abstract

Antinuclear antibodies are present in the serum of individuals with systemic autoimmune diseases such as SLE. Most autoantibodies characterized to date are directed against isolated nuclear molecules such as DNA or histones. We have obtained from spontaneously autoimmune mice six IgG mAb that recognize conformational nucleosome epitopes, but do not react with individual histones or DNA. For three of these mAb, the epitope is at least partially present in the H2A-H2B-DNA nucleosome subparticle, although their binding characteristics differ from those of conventional anti-H2A-H2B-DNA antibodies. All six mAb use VH or Vkappa genes which are recurrently utilized in anti-DNA and other antinuclear antibodies. The V regions of the nucleosome-reactive mAb also contain charged (mostly cationic) residues at sites that are likely to be critical for interaction with nucleosomal antigens. These results suggest that the usage of certain V gene segments in conjunction with suitable V(D)J rearrangements may confer reactivity to nucleosomal antigens. B cells producing such autoantibodies are probably expanded early during the autoimmune process. Somatic mutations in the V regions of nucleosome-reactive mAb may modulate their specificities and result in the acquisition of binding patterns restricted to individual chromatin components such as DNA.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8604228     DOI: 10.1016/0161-5890(95)00115-8

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  9 in total

1.  Divergent members of a single autoreactive B cell clone retain specificity for apoptotic blebs.

Authors:  Indira Neeli; Mekel M Richardson; Salar N Khan; Danielle Nicolo; Marc Monestier; Marko Z Radic
Journal:  Mol Immunol       Date:  2006-11-03       Impact factor: 4.407

2.  An active mechanism flanks and modulates the export of the small ribosomal subunits.

Authors:  Barbara Cisterna; Manuela Malatesta; Jürgen Dieker; Sylviane Muller; Ennio Prosperi; Marco Biggiogera
Journal:  Histochem Cell Biol       Date:  2009-03-18       Impact factor: 4.304

3.  An epichromatin epitope: persistence in the cell cycle and conservation in evolution.

Authors:  Ada L Olins; Markus Langhans; Marc Monestier; Andreas Schlotterer; David G Robinson; Corrado Viotti; Hanswalter Zentgraf; Monika Zwerger; Donald E Olins
Journal:  Nucleus       Date:  2011 Jan-Feb       Impact factor: 4.197

4.  Autoimmunity caused by disruption of central T cell tolerance. A murine model of drug-induced lupus.

Authors:  A Kretz-Rommel; S R Duncan; R L Rubin
Journal:  J Clin Invest       Date:  1997-04-15       Impact factor: 14.808

5.  Cell-intrinsic expression of TLR9 in autoreactive B cells constrains BCR/TLR7-dependent responses.

Authors:  Kerstin Nündel; Nathaniel M Green; Arthur L Shaffer; Krishna L Moody; Patricia Busto; Dan Eilat; Kensuke Miyake; Michael A Oropallo; Michael P Cancro; Ann Marshak-Rothstein
Journal:  J Immunol       Date:  2015-02-13       Impact factor: 5.422

6.  TLR9 regulates TLR7- and MyD88-dependent autoantibody production and disease in a murine model of lupus.

Authors:  Kevin M Nickerson; Sean R Christensen; Jonathan Shupe; Michael Kashgarian; Daniel Kim; Keith Elkon; Mark J Shlomchik
Journal:  J Immunol       Date:  2010-01-20       Impact factor: 5.422

7.  The role of microparticles in the generation of immune complexes in murine lupus.

Authors:  Anirudh J Ullal; David S Pisetsky
Journal:  Clin Immunol       Date:  2012-10-13       Impact factor: 3.969

8.  Natural antibody to apoptotic cell membranes inhibits the proinflammatory properties of lupus autoantibody immune complexes.

Authors:  Jaya Vas; Caroline Grönwall; Ann Marshak-Rothstein; Gregg J Silverman
Journal:  Arthritis Rheum       Date:  2012-10

9.  Murine lupus is neutrophil elastase-independent in the MRL.Faslpr model.

Authors:  Rachael A Gordon; Jeremy S Tilstra; Anthony Marinov; Kevin M Nickerson; Sheldon I Bastacky; Mark J Shlomchik
Journal:  PLoS One       Date:  2020-04-03       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.